Vir Biotechnology, Inc. Revenue from Contract with Customer, Excluding Assessed Tax
Vir Biotechnology, Inc. (VIR) reported Revenue from Contract with Customer, Excluding Assessed Tax of $68.56 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-02-23
- Vir Biotechnology, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $64.07M, a 417.78% increase year-over-year.
- Vir Biotechnology, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $240.00K, a 89.92% decline year-over-year.
- Vir Biotechnology, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-06-30 was $1.21M, a 60.52% decline year-over-year.
- Vir Biotechnology, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-03-31 was $3.03M, a 94.62% decline year-over-year.
- Vir Biotechnology, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $68.56M, a 7.61% decline from fiscal 2024.
- Vir Biotechnology, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $74.20M, a 13.90% decline from fiscal 2023.
- Vir Biotechnology, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $86.18M, a 94.67% decline from fiscal 2022.
- Vir Biotechnology, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $1.62B.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2025-12-31 | $64.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $64.31M derived: sum of 2 quarters · filed 2026-02-23 | $65.52M derived: sum of 3 quarters · filed 2026-02-23 | $68.56M 10-K · filed 2026-02-23 |
| 2025-09-30 | $240.00K 10-Q · filed 2025-11-05 | $1.45M derived: sum of 2 quarters · filed 2025-11-05 | $4.49M 10-Q · filed 2025-11-05 | $16.86M derived: sum of 4 quarters · filed 2026-02-23 |
| 2025-06-30 | $1.21M 10-Q · filed 2025-08-06 | $4.25M 10-Q · filed 2025-08-06 | $16.62M derived: sum of 3 quarters · filed 2026-02-23 | $19.00M derived: sum of 4 quarters · filed 2026-02-23 |
| 2025-03-31 | $3.03M 10-Q · filed 2025-05-08 | $15.41M derived: sum of 2 quarters · filed 2026-02-23 | $17.79M derived: sum of 3 quarters · filed 2026-02-23 | $20.86M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-12-31 | $12.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $14.75M derived: sum of 2 quarters · filed 2026-02-23 | $17.83M derived: sum of 3 quarters · filed 2026-02-23 | $74.20M 10-K · filed 2026-02-23 |
| 2024-09-30 | $2.38M 10-Q · filed 2025-11-05 | $5.46M derived: sum of 2 quarters · filed 2025-11-05 | $61.83M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $3.08M 10-Q · filed 2025-08-06 | $59.45M 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | $56.38M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $86.18M 10-K · filed 2026-02-23 | |||
| 2022-12-31 | $1.62B 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |